Last reviewed 2026-04-20 · How we verify

Nplate

At a glance

Approved indications

• Aplastic anemia
• Chronic idiopathic thrombocytopenic purpura

Common side effects

• Headache
• Bronchitis
• Sinusitis
• Upper respiratory tract infection
• Cough
• Nausea
• Vomiting
• Diarrhea
• Oropharyngeal pain
• Dizziness
• Arthralgia
• Myalgia

Serious adverse events

• Bone marrow fibrosis with collagen
• Bone marrow collagen fibrosis (Grade 4)
• Bone marrow reticulin formation progression
• Thrombocytosis

Key clinical trials

• Single Arm Romiplostim to Prevent CIT (EARLY_PHASE1)
• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
• A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (PHASE2)
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (PHASE3)
• Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (PHASE2)
• Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy (PHASE2)
• Romiplostim N01 for Platelet Recovery After Haploidentical HSCT (PHASE1)
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nplate CI brief — competitive landscape report
• Nplate updates RSS · CI watch RSS
• Nantes University Hospital portfolio CI